Equine NK-lysin The equine NK-lysin was described by Davis et al
Generally, patients may notice improvements in their blood sugar levels within a few weeks
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes
Krolewski Research Division, Joslin Diabetes Center and Harvard Medical School Kevin Duffin Vice President, Aging Research, Eli Lilly Jonathan Wilson Senior Director, Eli Lilly and Company Pavo Imre Senior Medical Director, Eli Lilly & Co, Vienna Fergus Fleming Co-founder, Executive Director and CTO, RenalytixAI Anna Nowak-Szwed, Eiichiro Satake, and Sok Cin Tye Joslin Diabetes Center / Harvard Medical School researchers advancing translational proteomics and kidney disease biomarker research #cardiometabolic #immunology #pathology #Proteomics #KidneyDisease #Nephrology #Diabetes #Biomarkers #GLP1 #Tirzepatide #Olink #PrecisionMedicine #TranslationalResearch #EliLilly To view or add a comment, sign in Diabetes Conference Abstract | June 5, 2026 Using the custom Joslin Kidney Panel (JKP), an #Olink Focus 21-marker #proteomics panel developed by Olink for Joslin Diabetes Center, researchers from Harvard Medical School/Joslin Diabetes Center and Eli Lilly and Company showed that treatment with the dual GLP-1/GIP receptor agonist tirzepatide (#Mounjaro) significantly reduced circulating protein #biomarkers associated with progression to end-stage #kidney disease (#ESKD) in patients with type 2 diabetes (#T2D)
We present B12 injections as a medical treatment for deficiency and an option to discuss with a provider for wellness goals
